A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Phase 4TerminatedNCT00140894

Merck Sharp & Dohme LLC62 enrolled

Overview

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females at least 18 years of age with familial adenomatous polyposis.

Number and average size of rectal polyps

Safety and tolerability

Number and average size of duodenal polyps

Proportions of patients with improved overall colon rating

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.